Corcept Therapeutics/$CORT
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
- Ticker
- $CORT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 730
- Headquarters
- Redwood City, United States
- Website
- www.corcept.com
CORT Metrics
BasicAdvanced
$13B
269.48
$0.45
0.46
-
Price and volume
Market cap
$13B
Beta
0.46
52-week high
$123.44
52-week low
$28.66
Average daily volume
1.2M
Financial strength
Current ratio
2.859
Quick ratio
2.504
Long term debt to equity
1.063
Total debt to equity
1.335
Profitability
EBITDA (TTM)
8.084
Gross margin (TTM)
98.30%
Net profit margin (TTM)
6.64%
Operating margin (TTM)
0.77%
Effective tax rate (TTM)
-109.27%
Revenue per employee (TTM)
$1,140,000
Management effectiveness
Return on assets (TTM)
0.47%
Return on equity (TTM)
8.23%
Valuation
Price to earnings (TTM)
269.479
Price to revenue (TTM)
15.342
Price to book
18.69
Price to tangible book (TTM)
18.69
Price to free cash flow (TTM)
119.21
Free cash flow yield (TTM)
0.84%
Free cash flow per share (TTM)
1.025
Growth
Revenue change (TTM)
16.02%
Earnings per share change (TTM)
-59.30%
3-year revenue growth (CAGR)
24.73%
10-year revenue growth (CAGR)
29.22%
3-year earnings per share growth (CAGR)
-17.60%
10-year earnings per share growth (CAGR)
47.69%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
CORT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.